510(k) K163367

GenetiSure Dx Postnatal Assay by Agilent Technologies, Inc. — Product Code PFX

Clearance Details

Decision
SESE (Substantially Equivalent)
Decision Date
August 11, 2017
Date Received
November 30, 2016
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device Classification

Device Name
System, Microarray-Based, Genome-Wide, Postnatal Chromosomal Abnormality Detection
Device Class
Class II
Regulation Number
866.5920
Review Panel
PA
Submission Type

A microarray-based, genome-wide, postnatal chromosomal abnormality detection system is used to qualitatively detect constitutional gains and losses in chromosomal copy numbers across the human genome using microarray methods. It is intended as an aid in the postnatal diagnosis of developmental delay and/or intellectual disability (DD/ID), congenital anomalies, and dysmorphic features in conjunction with other clinical information currently used in postnatal diagnosis. It is not intended to be used for standalone diagnostic purposes, prenatal or pre-implantation testing or screening, population screening, or for the detection of, or screening for, acquired or somatic genetic aberrations.